Chemistry:Gevotroline

From HandWiki
Revision as of 23:05, 5 February 2024 by WikiG (talk | contribs) (linkage)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Short description: Chemical compound
Gevotroline
Gevotroline.svg
Clinical data
Routes of
administration
Oral
ATC code
  • None
Legal status
Legal status
  • In general: uncontrolled
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEBI
Chemical and physical data
FormulaC19H20FN3
Molar mass309.388 g·mol−1
3D model (JSmol)

Gevotroline (WY-47,384) is an atypical antipsychotic with a tricyclic structure which was under development for the treatment of schizophrenia by Wyeth-Ayerst.[1][2][3] It acts as a balanced, modest affinity D2 and 5-HT2 receptor antagonist and also possesses high affinity for the sigma receptor.[2][4][5][6] It was well tolerated and showed efficacy in phase II clinical trials but was never marketed.[2][3]

See also

References

  1. Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. 1996. ISBN 0-412-46630-9. https://books.google.com/books?id=Z_mfTTIApVEC. 
  2. 2.0 2.1 2.2 "Novel Antipyschotic Agents". Annual Reports in Medicinal Chemistry (Boston: Academic Press) 25: 1–10. 1990. doi:10.1016/S0065-7743(08)61577-8. ISBN 0-12-040525-3. https://books.google.com/books?id=NZZbEkldeJAC&q=gevotroline&pg=PA2. 
  3. 3.0 3.1 "A Review of the Pharmacology of New Antipsychotic Drugs". CNS neurotransmitters and neuromodulators: dopamine. Boca Raton: CRC Press. 1996. ISBN 0-8493-7632-7. https://books.google.com/books?id=ObG24oxrivEC&q=gevotroline&pg=PA187. 
  4. "Receptor mechanisms in antipsychotic drug action: focus on sigma receptors". The Journal of Neuropsychiatry and Clinical Neurosciences 1 (1): 7–15. 1989. doi:10.1176/jnp.1.1.7. PMID 2577720. 
  5. "Sigma receptor ligands alter concentrations of corticosterone in plasma in the rat". Neuropharmacology 30 (1): 79–87. January 1991. doi:10.1016/0028-3908(91)90046-E. PMID 1675451. 
  6. "Neuroendocrinological and neurochemical effects of sigma ligands". Neuropharmacology 31 (2): 157–162. February 1992. doi:10.1016/0028-3908(92)90026-L. PMID 1348112.